Sleijfer Stefan, van der Gaast Ate, Planting André S Th, Stoter Gerrit, Verweij Jaap
Department of Medical Oncology, Daniel den Hoed Cancer Center, Erasmus University Medical Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands.
Eur J Cancer. 2005 Mar;41(4):516-22. doi: 10.1016/j.ejca.2004.12.009. Epub 2005 Jan 11.
Statins are known to reduce mortality related to cardiovascular diseases. In recent years, evidence has accumulated that statins also exert anti-tumour activity for which numerous potential underlying mechanisms of action have been suggested. Accordingly, several case-control studies showed a reduction in cancer incidence in patients treated with statins. Furthermore, statins interact synergistically with several anti-tumour treatments in preclinical studies. Until now, only a few clinical studies are available that explore the optimal dose, feasibility, and efficacy of statins applied as single agents to control the growth of existing tumours. Studies investigating statins as part of a multi-drug regimen are completely lacking. Nevertheless, the interesting pre-clinical anti-tumour activity of statins combined with a favourable toxicity profile warrant their further development as anti-tumour agents, in particular as part of multi-drug regimens.
他汀类药物已知可降低心血管疾病相关的死亡率。近年来,越来越多的证据表明,他汀类药物还具有抗肿瘤活性,人们提出了许多潜在的作用机制。因此,几项病例对照研究表明,接受他汀类药物治疗的患者癌症发病率有所降低。此外,在临床前研究中,他汀类药物与几种抗肿瘤治疗具有协同作用。到目前为止,仅有少数临床研究探讨了他汀类药物作为单一药物控制现有肿瘤生长的最佳剂量、可行性和疗效。完全缺乏将他汀类药物作为多药方案一部分的研究。尽管如此,他汀类药物有趣的临床前抗肿瘤活性以及良好的毒性特征,使其有理由作为抗肿瘤药物进一步开发,特别是作为多药方案的一部分。